Shingen Misaka1, Osamu Abe2,3, Hideyuki Sato4, Tomoyuki Ono2, Yayoi Shikama2,5, Satomi Onoue4, Hirooki Yabe3, Junko Kimura2. 1. Department of Pharmacology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 9601295, Japan. misaka@fmu.ac.jp. 2. Department of Pharmacology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 9601295, Japan. 3. Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan. 4. Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan. 5. Center for Medical Education and Career Development, Fukushima Medical University School of Medicine, Fukushima, Japan.
Abstract
PURPOSE: The objective of this study is to assess the effects of green tea and its major catechin component, (-)-epigallocatechin gallate (EGCG), on CYP2C9-mediated substrate metabolism in vitro, and the pharmacokinetics of fluvastatin in healthy volunteers. METHODS: The metabolism of diclofenac and fluvastatin in human recombinant CYP2C9 was investigated in the presence of EGCG. In a randomized three-phase crossover study, 11 healthy volunteers ingested a single 20-mg dose of fluvastatin with green tea extract (GTE), containing 150 mg of EGCG, along with water (300 mL), brewed green tea (300 mL), or water (300 mL) after overnight fasting. Plasma concentrations of fluvastatin and EGCG were measured by ultra-performance liquid chromatography with fluorescence detection and a single mass spectrometer. RESULTS:EGCG inhibited diclofenac 4'-hydroxylation and fluvastatin degradation with IC50 of 2.23 and 48.04 μM, respectively. Brewed green tea used in the clinical study also dose-dependently inhibited the metabolism of diclofenac and fluvastatin in vitro. However, no significant effects of GTE and brewed green tea were observed in plasma concentrations of fluvastatin. The geometric mean ratios with 90% CI for area under the plasma concentration-time curve (AUC0-∞) of fluvastatin were 0.993 (0.963-1.024, vs. brewed green tea) and 0.977 (0.935-1.020, vs. GTE). CONCLUSIONS: Although in vitro studies indicated that EGCG and brewed green tea produce significant inhibitory effects on CYP2C9 activity, the concomitant administration of green tea and fluvastatin in healthy volunteers did not influence the pharmacokinetics of fluvastatin.
RCT Entities:
PURPOSE: The objective of this study is to assess the effects of green tea and its major catechin component, (-)-epigallocatechin gallate (EGCG), on CYP2C9-mediated substrate metabolism in vitro, and the pharmacokinetics of fluvastatin in healthy volunteers. METHODS: The metabolism of diclofenac and fluvastatin in human recombinant CYP2C9 was investigated in the presence of EGCG. In a randomized three-phase crossover study, 11 healthy volunteers ingested a single 20-mg dose of fluvastatin with green tea extract (GTE), containing 150 mg of EGCG, along with water (300 mL), brewed green tea (300 mL), or water (300 mL) after overnight fasting. Plasma concentrations of fluvastatin and EGCG were measured by ultra-performance liquid chromatography with fluorescence detection and a single mass spectrometer. RESULTS:EGCG inhibited diclofenac 4'-hydroxylation and fluvastatin degradation with IC50 of 2.23 and 48.04 μM, respectively. Brewed green tea used in the clinical study also dose-dependently inhibited the metabolism of diclofenac and fluvastatin in vitro. However, no significant effects of GTE and brewed green tea were observed in plasma concentrations of fluvastatin. The geometric mean ratios with 90% CI for area under the plasma concentration-time curve (AUC0-∞) of fluvastatin were 0.993 (0.963-1.024, vs. brewed green tea) and 0.977 (0.935-1.020, vs. GTE). CONCLUSIONS: Although in vitro studies indicated that EGCG and brewed green tea produce significant inhibitory effects on CYP2C9 activity, the concomitant administration of green tea and fluvastatin in healthy volunteers did not influence the pharmacokinetics of fluvastatin.
Entities:
Keywords:
(−)-Epigallocatechin gallate; CYP2C9; Diclofenac; Fluvastatin; Green tea; Pharmacokinetics
Authors: Bruce K Birmingham; Sarah R Bujac; Robert Elsby; Connie T Azumaya; Cheryl Wei; Yusong Chen; Rogelio Mosqueda-Garcia; Helen J Ambrose Journal: Eur J Clin Pharmacol Date: 2015-02-12 Impact factor: 2.953
Authors: H-H Sherry Chow; Iman A Hakim; Donna R Vining; James A Crowell; James Ranger-Moore; Wade M Chew; Catherine A Celaya; Steven R Rodney; Yukihiko Hara; David S Alberts Journal: Clin Cancer Res Date: 2005-06-15 Impact factor: 12.531
Authors: Manthena V Varma; Charles J Rotter; Jonathan Chupka; Kevin M Whalen; David B Duignan; Bo Feng; John Litchfield; Theunis C Goosen; Ayman F El-Kattan Journal: Mol Pharm Date: 2011-07-11 Impact factor: 4.939
Authors: Mary F Paine; Heather L Hart; Shana S Ludington; Robert L Haining; Allan E Rettie; Darryl C Zeldin Journal: Drug Metab Dispos Date: 2006-02-07 Impact factor: 3.922